Výsledky vyhledávání - "Toshiaki Nojima"

Akademický článek

Effects of pemafibrate on glucose metabolism markers and liver function tests in patients with hypertriglyceridemia: a pooled analysis of six phase 2 and phase 3 randomized double‐blind placebo‐controlled clinical trials

Autor: Koutaro Yokote, Shizuya Yamashita, Hidenori Arai, Eiichi Araki, Mitsunori Matsushita, Toshiaki Nojima, Hideki Suganami, Shun Ishibashi

Publikováno v: Cardiovascular Diabetology, Vol 20, Iss 1, Pp 1-13 (2021)

Abstract Background Increased risk of cardiovascular events is associated not only with dyslipidemias, but also with abnormalities in glucose metabolism and liver function. This study uses pooled analysis to explore the in-depth effects of pemafibrat

Externí odkaz: https://doaj.org/article/8801d36fb05c4191a9b34754df7d9a8d

Zobrazit plný text záznamu

Akademický článek

Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator (SPPARMα): Pooled Analysis of Phase 2 and 3 Studies in Dyslipidemic Patients with or without Statin Combination

Autor: Shizuya Yamashita, Hidenori Arai, Koutaro Yokote, Eiichi Araki, Mitsunori Matsushita, Toshiaki Nojima, Hideki Suganami, Shun Ishibashi

Publikováno v: International Journal of Molecular Sciences, Vol 20, Iss 22, p 5537 (2019)

Hypertriglyceridemia has emerged as an independent risk factor for cardiovascular events, despite low-density lipoprotein-cholesterol (LDL-C) well-controlled with statins. We pooled data from the first 12 weeks of six randomized double-blind placebo-

Externí odkaz: https://doaj.org/article/430f0c9a8f704f5b9ee550663653ac61

Zobrazit plný text záznamu

Plný text ve formátu HTML

Randomised clinical trial: Pemafibrate, a novel selective peroxisome proliferator‐activated receptor α modulator (SPPARMα), versus placebo in patients with non‐alcoholic fatty liver disease

Autor: Yuichiro Eguchi, Atsushi Nakajima, Hideki Suganami, Ryohei Tanigawa, Yuki Iida, Nobuharu Tamaki, Rohit Loomba, Toshiaki Nojima, Kento Imajo, Masato Yoneda, Masakazu Iizuka

Publikováno v: Alimentary Pharmacology & Therapeutics. 54:1263-1277

Background Pemafibrate is a novel, selective peroxisome proliferator-activated receptor α modulator (SPPARMα). In mice, Pemafibrate improved the histological features of non-alcoholic steatohepatitis (NASH). In patients with dyslipidaemia, it impro

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ba43a76b877bfd8ec5e7cb5f911b841a
https://doi.org/10.1111/apt.16596

Zobrazit plný text záznamu

Plný text ve formátu HTML

Ripasudil-brimonidine Fixed-dose Combination vs. Ripasudil or Brimonidine; Two Phase 3 Randomized Clinical Trials

Autor: Hidenobu Tanihara, Tetsuya Yamamoto, Makoto Aihara, Koji Kawakita, Satoshi Kojima, Mizuho Kanazawa, Toshiaki Nojima, Hideki Suganami

Publikováno v: American journal of ophthalmology.

To confirm the superiority of the intraocular pressure (IOP)-lowering effect of the ripasudil-brimonidine fixed-dose combination (RBFC, K-232) to ripasudil 0.4% or brimonidine 0.1% ophthalmic solution.Two multicenter, randomized, double- or single-ma

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::87e965331e2f3e3d025e64241ae73487
https://pubmed.ncbi.nlm.nih.gov/36410471

Zobrazit plný text záznamu

Evaluation of Data Errors and Monitoring Activities in a Trial in Japan Using a Risk-Based Approach Including Central Monitoring and Site Risk Assessment

Autor: Hidenobu Kondo, Kenji Fujisawa, Yukikazu Hayashi, Takuhiro Yamaguchi, Toshiaki Nojima, Hideki Suganami, Tomoaki Kamiyoshihara, Hisataka Fujiwara, Ryohei Tanigawa

Publikováno v: Therapeutic Innovation & Regulatory Science

Background Risk-based monitoring (RBM) is a slow uptake in some trial sponsors. There are three main reasons for this. First, there is the fear of making large investments into advanced RBM technology solutions. Second, it is considered that RBM is m

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::83789ce8a9a3288ca158d342281f685f
http://europepmc.org/articles/PMC8238712

Zobrazit plný text záznamu

LIP REJUVENATION WITH HYALURONIC ACID

Autor: Hennaly Silva Dantas, Ashley, Vanessa Machado Bezerra, Rosane, Toshiaki Nojima, Carlos, Matheus de Andrade Lira, Kainã, Dias Gomes da Silva, Gustavo, Galindo de Oliveira, Janaina, Gomes Moreira, Andréia

Publikováno v: Health and Society; Vol. 2 No. 02 (2022)
Health and Society; v. 2 n. 02 (2022)
Health and Society
Instituto de Ensino e Pesquisa Periodicojs
instacron:IEPP

In Dentistry, the search for positive changes in the aesthetics of the smile has been increasing and with that the objectives have become broader, not being restricted only to the teeth, but also treating both the functional and aesthetic parts of th

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::05b50964fe83a3314a1629d4b666e330
https://doi.org/10.51249/hs.v2i02.748

Zobrazit plný text záznamu

Attenuation of Weight Loss Through Improved Antilipolytic Effect in Adipose Tissue Via the SGLT2 Inhibitor Tofogliflozin

Autor: Kazuya Fujihara, Hirohito Sone, Masahiro Ishizawa, Hideki Suganami, Shiro Tanaka, Toshiaki Nojima, Takahiro Abe, Akihiro Yoshida, Yasuhiro Matsubayashi, Kohei Kaku

Publikováno v: The Journal of Clinical Endocrinology & Metabolism. 104:3647-3660

Context Although calorie loss from increased urinary glucose excretion continues after long-term treatment with sodium-glucose cotransporter 2 inhibitors (SGLT2is), the mechanisms of the attenuated weight loss due to SGLT2is are not well known. Objec

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9cbc5ed049a7d28ba541d60a793021ff
https://doi.org/10.1210/jc.2018-02254

Zobrazit plný text záznamu

Autor: Eiichi Araki, Mitsunori Matsushita, Shun Ishibashi, Hideki Suganami, Hidenori Arai, Toshiaki Nojima, Koutaro Yokote, Shizuya Yamashita

Publikováno v: Cardiovascular Diabetology
Cardiovascular Diabetology, Vol 20, Iss 1, Pp 1-13 (2021)

BackgroundIncreased risk of cardiovascular events is associated not only with dyslipidemias, but also with abnormalities in glucose metabolism and liver function. This study uses pooled analysis to explore the in-depth effects of pemafibrate, a selec

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b880148a9a5b494824dfaab45f2ed75d
http://europepmc.org/articles/PMC8097867

Zobrazit plný text záznamu

1133-P: Association of Higher Baseline BNP Levels with a Greater Reduction in Plasma Volume and Increase in Beta-Hydroxybutyrate via the SGLT2 Inhibitor Tofogliflozin in Type 2 Diabetes

Autor: Hirohito Sone, Shiro Tanaka, Yasuhiro Matsubayashi, Kohei Kaku, Hideki Suganami, Akihiro Yoshida, Momoko Oe, Toshiaki Nojima, Kazuya Fujihara

Publikováno v: Diabetes. 69

Reduced plasma volume (PV) to decrease ventricular filling pressure and increased beta-hydroxybutyrate (BHB) as a substitute for the energy source by SGLT2 inhibitors (SGLT2is) might contribute to preserving the heart in type 2 diabetes mellitus (T2D

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::bc0f40ff3126b585d86ea660b2711b69
https://doi.org/10.2337/db20-1133-p

Zobrazit plný text záznamu

1125-P: Association of Plasma Volume with Body Weight and BNP after Long-Term Administration and Subsequent Withdrawal of the SGLT2 Inhibitor Tofogliflozin

Autor: Hideki Suganami, Toshiaki Nojima, Kohei Kaku, Hirohito Sone, Akihiro Yoshida, Kazuya Fujihara, Yasuhiro Matsubayashi

Publikováno v: Diabetes. 69

SGLT2 inhibitors (SGLT2is) promote diuresis and reduce plasma volume (PV). However, the impact of long-term administration and subsequent withdrawal of SGLT2is on PV is little known. This study investigated the effect of long-term administration and

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d3ce7f9fd122ed0531b0e77883c1e998
https://doi.org/10.2337/db20-1125-p

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání